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Background. Following high-dose chemotherapy/bone marrow transplantation, patients 
are routinely, prophylactically transfused with platelet concentrates (PC) if they have a platelet 
count ≤10×109/L or higher in the presence of risk factors for bleeding. However, whether such 
transfusions are necessary in clinically stable patients with no bleeding, or whether a therapeutic 
transfusion strategy could be sufficient and safe, is still debated.
Materials and methods. The GIMEMA Haemostasis and Thrombosis Working Party sent 
a questionnaire to Italian haematology departments to survey several aspects of daily platelet 
transfusion practice, such as the cut-off platelet count for transfusion, the evaluation of refractoriness 
and the type of PC administered.
Results The questionnaire was answered by 18 out of 31 centres (58%). A total of 23,162 PC were 
transfused in 2,396 patients in 2013. The vast majority of centres (95%) transfused PC according to 
Italian and international guidelines; only a few transfused always at platelet counts ≤20×109/L. The 
broad agreement on platelet count cut-off for transfusion (≤10×109/L) was not confirmed when the 
World Health Organization (WHO) bleeding score was considered: only a third of centres (33%) used 
transfusions as recommended when the bleeding grade was ≥2. Platelet refractoriness was poorly 
monitored and most centres (89%) evaluated, mostly empirically (67%), response to transfusion only 
24 hours later. Thirty percent of centres transfused platelets in asymptomatic refractory patients.
Discussion. Although most Italian haematology departments transfuse PC according to Ital-
ian and international guidelines, our survey shows that in routine daily practice physicians do not 
comply closely with the WHO recommendations on platelet transfusions and monitoring platelet 
refractoriness. This causes excessive platelet transfusions, with a resulting increase of costs and 
waste of public health resources.
Keywords: bleeding, platelet transfusion, prophylaxis, high-dose chemotherapy, bone marrow 
transplantation.
Introduction
Patients with blood malignancies are often treated 
by myeloablative chemotherapy resulting in severe and 
prolonged hypo-regenerative cytopenias. Although fatal 
bleeding is rare, the risk of haemorrhage represents a 
challenge for patients and physicians and it is a standard 
of care to support patients with platelet transfusions1,2. 
Platelets are transfused prophylactically if patients have 
a platelet count below 10×109/L or higher in the presence 
of fever or infection or when grade 2 or higher bleeding, 
according to the World Health Organization (WHO) 
scale, is present3-5 (Table I). 
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However, whether prophylactic transfusions are 
necessary in patients who are clinically stable and 
asymptomatic, or whether a therapeutic transfusion 
strategy could be sufficient and safe, is still debated6-8.
Thirty years ago, small controlled studies9-12 showed 
favourable results supporting the prophylactic strategy, 
but there is evidence that a platelet count transfusion 
trigger of ≤10×109/L is equally as safe as a trigger of 
≤20×109/L in controlling bleeding3.
This practice of prophylactic platelet transfusions, 
together with the wider diffusion of high-dose 
chemotherapy and stem cell transplantation programmes, 
has increased the requests for blood products and more 
stringent approaches to platelet transfusion have been 
explored. Two important, recent studies compared 
prophylactic transfusions to "on demand" transfusions 
for active bleeding and, although both confirmed 
the value of prophylactic transfusions, "on demand" 
treatment might become the standard of care in some 
subgroups of patients13,14. 
There is a broad consensus regarding the need for 
prophylactic platelet transfusions when a patient's 
platelet count is ≤10×109/L, although the debate is still 
ongoing and some recommendations have tried to reduce 
the limit further to ≤5×109/L1,15. There are economic 
issues (costs), organisational aspects (supply) and 
medical concerns associated with platelet transfusions. 
Although post-transfusion viral infections are now 
very rare, bacterial infections and sepsis have become 
more frequent (platelets are blood products stored at 
room temperature) and the risks of plasma allergic 
reactions and immunogenicity should not be overlooked. 
Immunological sensitisation to human leucocyte 
antigens (HLA) and human platelet antigens (HPA) may 
result in lack of efficacy and refractoriness to platelet 
transfusions, the latter occurring in approximately 20-
30% of patients16,17.
Conventionally refractoriness occurs if the platelet 
count increase, calculated 1 hour and/or 24 hours after 
the transfusion, is less than 7.5×109/L or 4.5×109/L, 
respectively, using the standard "formula" (Figure 1) 
and the results are confirmed on at least two consecutive 
occasions. In fact, a correct platelet count increase, 
followed by a reduction after 24 hours may be due to 
increased consumption induced by non-immunological 
causes such as fever, sepsis, splenomegaly, active 
bleeding, disseminated intravascular coagulation or 
administration of amphotericin B18,19.
The aim of the present survey was to evaluate the 
standard trough level at which patients receive platelet 
transfusions and to assess how "refractory" patients are 
managed in Italian haematology departments. Currently 
in Italy approximately 150-200,000 units of platelet 
concentrates are transfused each year, at a total cost of 
about 40 million euros. Given that the resources involved 
are substantial, this survey could contribute to the 
debate on the best management of platelet transfusions 
by determining the real-life approach in several Italian 
haematology departments.
Material and methods
The GIMEMA Haemostasis and Thrombosis Working 
Party designed a questionnaire (Figure 1) to be delivered 
to experts in haemostasis and thrombosis working in 
haematology departments to cover platelet transfusions 
in the whole of 2013. Thirty-one haematology 
departments were contacted to investigate daily practice 
in the transfusion of platelet concentrates, such as the 
cut-off platelet count for transfusion, the evaluation 
of refractoriness and the type of platelet concentrates 
transfused. The platelet transfusion policy in the 
following circumstances was investigated specifically: 
a) patient in a stable condition without complications 
and platelet count ≤10×109/L;
b) patient with active bleeding, in the presence of fever 
>38 °C, rapid drop in platelet count, or infection with 
a platelet count ≤20×109/L.
Questions were also asked on how to evaluate and 
reduce the risk of platelet refractoriness or prolong the 
life of transfused platelets by using ABO-compatible 
platelet concentrates or selected HLA-matched platelet 
donors. Finally, costs were compared according to the 
type of concentrates administered: derived from a pool 
or obtained by apheresis.
Results
Eighteen out of the 31 (58%) centres involved in 
this survey answered the questionnaire. The results are 
reported in Tables II and III. A total of 23,162 platelet 
concentrates were transfused in 2,396 patients. The 
vast majority of centres (95%) transfused according to 
the Italian and international guidelines3,20,21 while only 
a few (5%) transfused always when the platelet count 
was below the level of 20×109/L. Interestingly, the broad 
agreement on the platelet count cut-off for transfusion 
(10×109/L) was not confirmed when WHO bleeding 
scores were considered (Table I). In fact only a minor 
proportion (33%) used transfusions as recommended by 
the WHO when the bleeding score was ≥2 (Table II).
Table I - WHO Bleeding Score
Grade 0 No bleeding
Grade 1 Petechiae, ecchymosis, occult blood in body secretions, etc.
Grade 2 Evidence of gross haemorrhage, not requiring red cell transfusion
Grade 3 Haemorrhage requiring transfusion
Grade 4 Life-threatening haemorrhage
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Figure 1 - Questionnaire on thrombocytopenia after high-dose chemotherapy sent 
by the GIMEMA Haemostasis and Thrombosis Working Party to Italian 
Haematology Departments.
Regarding refractoriness to platelet concentrates 
only a few haematology departments (11%) evaluated 
the platelet count 1 hour after the end of transfusion, 
while the vast majority (89%) did so after 24 hours. 
However, only 28% of these used the corrected count 
increment formula (Figure 1 and Table III), while 
empirical assessments, based on laboratory data 
routinely acquired 24 hours later, were prevalent 
(67%). Although 70% of haematology departments 
transfused refractory patients only when bleeding, 
30% still continued to transfuse platelets regardless of 
the increase observed (Table III). These results show 
that platelet transfusions are more widely used than 
necessary in clinical practice and that patients are often 
transfused also in the case of minor bleeding such as 
petechiae and mild epistaxis. 
The detailed responses to the questionnaire on the 
total amount and the types of platelet concentrates are 
reported in Tables IV and V.
Discussion
The first randomised trial on a platelet transfusion 
threshold in patients with blood malignancies, published 
in the 1990s3, was performed when there were fewer 
patients undergoing bone marrow transplantation (BMT) 
and high-dose chemotherapy and the platelet availability 
seemed sufficient to ensure transfusions for all those who 
needed them. The now widespread use of chemotherapy 
and autologous and allogeneic BMT has led to a dramatic 
increase in the number of patients potentially requiring 
platelet transfusion and availability has reached a 
critical point. This is one of the reasons why some 
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Table II -  Clinical and laboratory data on platelet transfusion 
criteria in 2013 in Italy.
Data from 18 haematology departments
Patients undergoing high-dose chemotherapy/BMT 2,396
PC transfused per high-dose chemotherapy/BMT 
(ratio) 
3.9
Total transfused PC 23,162
Platelet count triggers for transfusion N (%)
Always with platelet count ≤10×109/L 17 (95%)
In symptomatic patients with platelet count     
between 10×109/L and 20×109/L
13 (72%)
Always with platelet count ≤ 20×109/L 1 (5%)
Definition of "symptomatic" N (%)
Fever, even <38 °C 3 (17%)
Fever >38° C 13 (72%)
All bleeding 11 (61%)
According to WHO bleeding score (WHO≥2) 6 (33%)
PC: platelet concentrate; BMT: bone marrow transplantation.
Table III - Efficacy assessment and platelet transfusion 
criteria*.
Efficacy assessment (platelet count) N (%)
After 1 hour 2 (11%)
After 24 hours 16 (89%)
Never 2 (11%)
Corrected count increment* N (%)
Yes, after 1 hour 2 (11%)
Yes, after 24 hours 5 (28%)
No, refractoriness assessed only empirically 12 (67%)
No, refractoriness not considered 2 (11%)
Platelet transfusion in patients defined refractory N (%)
When platelet count ≤10×109/L 3 (15%)
When platelet count between 10x109/L and 20×109/L 2 (10%)
When platelet count ≤20×109/L 1 (5%)
Only in the case of bleeding 14 (70%)
*The total number of answers exceeds the number of Haematology 
Departments as some departments gave multiple answers.
Table IV - Platelet concentrates should contain, in 
accordance with current legislation, at least 
2-3×1011 platelets independently of whether 
they are produced from pooled buffy coats or 
apheresis19,20.
Platelet count in PCs 
Type of PCs Plts standard content
PC from a single unit of whole blood 0.45-0.85×1011
PC from a buffy coat pool: minimum content 2.5×1011
PC from apheresis: minimum content 3×1011
PC from plasma-platelet-apheresis or from a 
multicomponent sample: minimum content 2×10
11
PC: platelet concentrate; plt: platelet. 
recent studies have focused on the possibility of reducing 
platelet transfusions in routine daily practice. Wandt et 
al.13 analysed 391 patients, 201 undergoing autologous 
BMT and 190 receiving intensive chemotherapy for acute 
myeloid leukaemia, who were randomised to receive 
platelet transfusions either prophylactically at a platelet 
count of ≤10×109/L or as "on demand" treatment. The rate 
of WHO grade 2 bleeding was higher in the "on demand" 
group, the incidence of grade 3 or 4 bleeding was similar 
in the two groups, and seven out of 13 grade 4 bleeds in 
the treatment group occurred in patients with a platelet 
count between 56×109/L and 11×109/L. This means that 
about half of the bleeds could have occurred equally in 
the group given prophylactic transfusions on the basis 
of the threshold platelet count of 10×109/L. The authors 
concluded that prophylaxis should still be the standard 
of care and that although "therapeutic transfusions only" 
might become daily practice, this should only be the case 
in selected centres for patients undergoing autologous 
BMT. Furthermore, the 10×109/L cut-off should remain 
for patients with acute myeloid leukaemia as the bleeding 
rate was higher in patients with leukaemia than in those 
who underwent autologous BMT13.
Similarly, in another recent, large trial14, patients 
undergoing autologous BMT or chemotherapy for cancer 
(420 and 178, respectively) were randomly assigned to 
receive either prophylactic platelet transfusions, or no 
prophylaxis, if the platelet count was <10×109/L. The 
results again supported the need for continued use of 
prophylactic platelet transfusions and showed the benefit 
of prophylaxis, as compared with no prophylaxis, in 
reduce bleeding. A very recent Cochrane review stated 
that, while it is reasonable to transfuse platelets to 
prevent bleeding according to the current transfusion 
policy, the evidence supporting this practice is often of 
low quality22. 
Table V - Total number, source and ABO compatibility 
of platelet concentrates transfused in 18 Italian 
Haematology Departments during 2013.
Total platelet concentrates 
(average 1,287/centre; range, 300-4,100)
23,162
Type of concentrate
  Pool 38%
  Apheresis 62%
ABO-compatible N (%)
  Yes 4 (25%)
  No 3 (20%)
  Partially 11 (55%)
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periods, except to stop a life-threatening bleed and 
yet major bleeding is reported in only 3/1,000 patients 
despite the severity of the thrombocytopenia25. Other 
useful experience comes from Jehovah's Witnesses, 
who refuse therapy with blood components. There are 
reports in the literature describing the possibility of these 
patients undergoing intensive chemotherapy and stem 
cell transplantation without transfusions26,27.
In its recent guidelines21, the American Association of 
Blood Banks still recommends transfusing hospitalised 
adult patients with a platelet count of ≤10×109/L to 
reduce the risk of spontaneous bleeding. Using this 
clinical practice, approximately 2.2 million platelet 
units are transfused annually in the USA at an expense 
of nearly one billion dollars28.
In Italy during 2013 about 200,000 platelet 
transfusions were carried out, 38% prepared from 
pooled buffy coats (cost approximately 123 Euro each) 
and 62% obtained by apheresis (245 Euro each), giving 
a total cost of around 40 million Euros. As there is no 
evidence that apheresis-derived platelets are better than 
pooled platelets, the cheaper option should be used in 
clinical practice29. 
Although no data are available from our survey, 
recent literature suggests that the "on demand" 
treatment strategy could become a new standard of 
care after autologous stem-cell transplantation while 
prophylactic platelet transfusions should remain 
the standard of care for patients with acute myeloid 
leukaemia. The new strategy should only be used by 
some haematology centres in which the staff are well 
trained and experienced in the new approach and can 
react in a timely way to the first signs of central nervous 
system bleeding.
Conclusions
Our survey suggests that, in routine daily practice, 
Italian haematologists adopt the worldwide criterion of a 
platelet count cut-off when deciding whether to transfuse 
platelet concentrates, but they pay less attention to the 
WHO recommendations on platelet transfusions for 
bleeding and on monitoring refractoriness. This causes 
an excess of platelet transfusions, more frequently 
prepared by apheresis than from pooled donors, with 
a resulting increase of costs and waste of public health 
resources. The GIMEMA Haemostasis and Thrombosis 
Working Party should collect more data and propose a 
national strategy to improve platelet transfusion practice, 
thereby saving money and reducing inappropriate use 
of this blood component. 
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Although the WHO bleeding score grades the type 
of intervention according to the severity (Table I), grade 
2 events are heterogeneous and may be considered to 
have significantly different clinical impact. On this 
background, the patients' and doctors' "perception" of the 
bleeding may play a major role in administering platelet 
concentrates even for mild haemorrhages. 
Refractoriness is a major, severe side effect of 
platelet transfusion and it is highly recommended 
that a platelet count is determined 1 hour after the 
end of transfusion in order to evaluate this effect23,24. 
However, this seems very uncommon with our survey 
finding that this is being done in only 11% of centres, 
while the platelet count is checked 24 hours after the 
transfusion in most haematology departments. Thus, our 
data seem to suggest that while bleeding is particularly 
feared, the risks of immunisation and refractoriness 
are underestimated. Although this accounts for a more 
cautious approach in clinical practice in Italy, it is at 
variance with recent literature as the transfusion/patient 
ratio was higher in our survey (3.6 vs 2.4 and 3.0)13,14. 
This seems to reflect the different approach in clinical 
practice compared to that in standardised clinical trials. 
In fact, patients in our survey were often transfused 
for minor bleeding (in 11 out of 18 centres, Table II), 
a practice more likely to be related to prudence than to 
the WHO bleeding score recommendations. 
Transfused platelets may have a shortened life-
span as a result of alloimmunisation to platelet and 
leucocyte antigens (HLA class I and platelet-specific 
antigens, mainly HPA1) and transfusion of fresh platelet 
concentrates or 2 hours after amphotericin B infusion19,20 
is recommended to prevent refractoriness and to prolong 
platelet survival. The transfusion of HLA-matched 
platelets does not seem to be a first-line strategy because 
it would need a large number of typed donors and would 
only be feasible in large centres (actually, only one in 
Italy), where there are donors whose HLA system has 
been characterised.
Another strategy to save platelets might be to 
transfuse at a lower platelet count, possibly below the 
5×109/L cut-off. This has been addressed by the British 
Committee for Standards in Haematology1, but it seems 
difficult to propose, in part because of poor accuracy 
of laboratory counts when the number of platelets is 
very low. The possibility that platelet transfusion is 
performed only on demand or on the basis of a lower 
cut-off (5×109/L) raises ethical considerations (risks) 
and practical problems (platelet counts). However the 
"on demand only strategy" might find further support 
from an analysis of other clinical scenarios. For example, 
prophylactic platelet transfusions are not indicated 
in patients with autoimmune thrombocytopenia, who 
may often have a platelet count <10×109/L for long 
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